Although AbbVie has lost patent exclusivity for its flagship drug, Humira, the company may soon be bigger and better.

The dividend is significant to AbbVie: The company is a Dividend King, with a decades-long history of yearly increases from when it was still part of Abbott Labs. Investors can probably expect mid ...

Pharmaceutical powerhouse AbbVie (NYSE: ABBV) has been a beast since it spun off from Abbott Laboratories in 2012. Over the past decade, the stock has averaged a dividend yield of 3.5% while ...

AbbVie (NYSE: ABBV) could be the poster child for how to effectively navigate a patent cliff. When Abbott Labs spun off ...

We recently compiled a list of the 10 Best Halal Dividend Stocks To Invest In. In this article, we are going to take a look ...

But a pair of treatments that launched in 2019 are already offsetting Humira's losses. Combined sales of Skyrizi, a psoriasis ...

The Dividend Kings underperformed in 2024. Read here to know about the top 18 most opportune Dividend Kings based on ...

This month, we explore the 125-year-old history of Abbott Laboratories and its most significant milestone to date – the creation of its own independent company, AbbVie. In 1888, a 30-year-old ...

Discover how to navigate inflation with long-term investments in resilient companies like Coca-Cola, AbbVie, and TC Energy.

Here is a selection of people starting new roles with Waterways Ireland, IOB, Eaton, AbbVie Ireland, Deloitte Ireland and ...

N-Power Medicine, backed by Merck GHI, announced the acquisition of Syapse Holdings. Samsung Biologics and LigaChem extended their ADC services deal. Publicis Worldwide merged with Leo Burnett to form ...

AbbVie CEO says psychiatric drug space challenging ... development after mid-stage trial failure December 11, 2024 Crown Laboratories would buy the anti-wrinkle injection maker Revance ...